Cardiology 2013. Part II.

Notes: Alessandri, N

Lanzi, L

Garante, C M

Tersigni, F

Sergiacomi, R

Petrassi, M

Di Matteo, A

Tufano, F

eng

Comparative Study

Italy

2013/04/26 06:00

Eur Rev Med Pharmacol Sci. 2013 Feb;17 Suppl 1:13-21.

URL: http://www.ncbi.nlm.nih.gov/pubmed/23436661

Author Address: Department of Cardiology, Sapienza University, Rome, Italy. Alessandrinicola@libero.it

 

 

Reference Type:  Journal Article

Record Number: 1025Author: Almenar, L., Zunzunegui, J. L., Baron, G., Carrasco, J. I., Gomez-Doblas, J. J., Comin, J., Barrios, V., Subirana, M. T. and Diaz-Molina, B.

Year: 2013

Title: Update on heart failure, heart transplant, congenital heart disease, and clinical cardiology

Journal: Rev Esp Cardiol

Volume: 66

Issue: 4

Pages: 290-7

Date: Apr

Short Title: Update on heart failure, heart transplant, congenital heart disease, and clinical cardiology

Alternate Journal: Revista espanola de cardiologia

ISSN: 1579-2242 (Electronic)

0300-8932 (Linking)

DOI: 10.1016/j.recesp.2012.10.022

Accession Number: 23317810

Abstract: In the year 2012, 3 scientific sections-heart failure and transplant, congenital heart disease, and clinical cardiology-are presented together in the same article. The most relevant development in the area of heart failure and transplantation is the 2012 publication of the European guidelines for heart failure. These describe new possibilities for some drugs (eplerenone and ivabradine); expand the criteria for resynchronization, ventricular assist, and peritoneal dialysis; and cover possibilities of percutaneous repair of the mitral valve (MitraClip((R))). The survival of children with hypoplastic left heart syndrome in congenital heart diseases has improved significantly. Instructions for percutaneous techniques and devices have been revised and modified for the treatment of atrial septal defects, ostium secundum, and ventricular septal defects. Hybrid procedures for addressing structural congenital heart defects have become more widespread. In the area of clinical cardiology studies have demonstrated that percutaneous prosthesis implantation has lower mortality than surgical implantation. Use of the CHA2DS2-VASc criteria and of new anticoagulants (dabigatran, rivaroxaban and apixaban) is also recommended. In addition, the development of new sequencing techniques has enabled the analysis of multiple genes. Full English text available from:www.revespcardiol.org/en.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205